Trial Drug Shows Preliminary Promise Against Ovarian
SUNDAY, Aug. 21 (HealthDay News) -- An experimental drug that's
shown promise against ovarian cancer caused by mutations in the
BRCA1 or BRCA2 genes may also be effective against ovarian cancer
not caused by those gene mutations, according to a new study.
Olaparib blocks the activity of a protein called poly ADP ribose
polymerase (PARP). Both PARP and BRCA proteins are involved in DNA
repair. Clinical trials of olaparib in patients with BRCA 1 and 2
mutations have yielded promising results, the study authors
In the new study, Canadian researchers say they're the first to
show that olaparib reduces tumor size in patients with
non-hereditary (sporadic) ovarian cancer, which is much more common
than BRCA-mutated ovarian cancers.
The phase 2 trial included 65 ovarian cancer patients who
received 400 milligrams of olaparib twice daily for four weeks.
Measurable tumor shrinkage was seen in 41 percent of patients with
BRCA mutations and in 24 percent of those without BRCA mutations,
the researchers said.
The study was published online Aug. 21 in
The Lancet Oncology.
Side effects were described as mild and included fatigue,
nausea, vomiting and decreased appetite, study lead author Karen
Gelmon, of the B.C. Cancer Agency in Vancouver, and colleagues said
in a news release from the journal.
"This finding not only suggests new therapeutic possibilities for women with this aggressive type of ovarian cancer, but also importantly confirms the hypothesis that subpopulations of patients with common sporadic tumors can be targeted effectively with PARP inhibitor therapy," Dr. Melinda Telli, of Stanford University School of Medicine, wrote in an accompanying editorial.
Another expert agreed. Dr. Stephanie V. Blank is an assistant
professor in clinical gynecologic oncology at NYU School of
Medicine. She said: "It is extremely exciting that an agent as
promising as olaparib can be effective in a broader group of women
than had been expected. The next challenge will lie in getting our
hands on the drug, which at present is only available for patients
on clinical trials."
The American Cancer Society outlines the
risk factors for ovarian cancer.
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.